Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Dev Biol. 2021 Jan 8;475:205–221. doi: 10.1016/j.ydbio.2020.12.018

Figure 5 -.

Figure 5 -

Oncogenic mechanisms of YAP1 fusions. Left: Regulation of wild type YAP1 activity by the Hippo pathway. Right: YAP1 fusion proteins are resistant to Hippo pathway-mediated regulation, due to both constitutive nuclear localization (mediated by the nuclear localization sequence present in the C-terminal fusion partner sequence) and resistance to proteasomal degradation (mediated by the loss of YAP1 S397 in the fusion protein). Figure was created with BioRender.com